Neil K. Warma, president and chief executive officer of Opexa. “The Novartis stem cell transaction bolstered our financial resources and consequently leaves us with $4.1 million in cash as of the end of October. Third Quarter... [read full story]
|
RELATED
|
|
THE WOODLANDS, Texas--(BUSINESS WIRE)--Opexa Therapeutics, Inc. (NASDAQ: OPXA - News), a company developing a novel T-cell therapy for multiple sclerosis (MS), today reported financial results for the quarter ended September...
Opexa Therapeutics, Inc. (NASDAQ: OPXA), a company developing a novel T-cell therapy for multiple sclerosis (MS), today reported financial results for the quarter ended September 30, 2009, and provided details on further...
THE WOODLANDS, Texas - Opexa Therapeutics, Inc. (NASDAQ: OPXA), a company developing a novel T-cell therapy for multiple sclerosis (MS), today reported financial results for the quarter ended September 30, 2009, and provided...
Finance, Banking & Insurance, Investing & Markets, Human Resources, Senior Management, Unemployment & Downsizing, General Management Issues, Corporate Legal Issues, Corporate Crime & Lawsuits, Financial Markets, Investing, Downsizing, CEO, Technology Transfer, Stock Markets, Novartis
